Enanta Pharmaceuticals (ENTA) EBT (2012 - 2026)
Enanta Pharmaceuticals (ENTA) reported EBT of -$13.1 million for Q1 2026, up 45.37% on a YoY basis from -$9.0 million in Q1 2025, and down 9.82% quarter-over-quarter from -$11.9 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) EBT (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals has reported EBT for 15 years, with the latest figure at -$13.1 million in Q1 2026.
- For the quarter ending Q1 2026, EBT rose 45.37% year-over-year to -$13.1 million; the trailing twelve-month figure through Mar 2026 stood at -$61.9 million (up 37.42% YoY), and the FY2025 full-year result was -$83.5 million, up 29.07% from the prior year.
- EBT for Q1 2026 stood at -$13.1 million, down from -$11.9 million in the prior quarter.
- The five-year high for EBT was -$11.9 million in Q4 2025, with the low at -$37.6 million in Q1 2023.
- Historically, EBT has averaged -$26.4 million across 5 years, with a median of -$29.0 million in 2022.
- Annual changes were most pronounced in 2023 — EBT decreased 17.26% — and 2025, when it soared 47.53%.
- Enanta Pharmaceuticals' EBT stood at -$29.0 million in 2022, then slipped by 17.26% to -$34.0 million in 2023, then soared by 33.27% to -$22.7 million in 2024, then soared by 47.53% to -$11.9 million in 2025, then decreased by 9.82% to -$13.1 million in 2026.
- The last three EBT figures came in at -$13.1 million (Q1 2026), -$11.9 million (Q4 2025), and -$18.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -15.31 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.18 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Enanta Pharmaceuticals | 343.24 Mn | 179.46 Mn | - | -13.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.08 Mn |
| Dec 31, 2025 | -11.91 Mn |
| Sep 30, 2025 | -18.67 Mn |
| Jun 30, 2025 | -18.23 Mn |
| Mar 31, 2025 | -23.95 Mn |
| Dec 31, 2024 | -22.71 Mn |
| Sep 30, 2024 | -29.19 Mn |
| Jun 30, 2024 | -23.05 Mn |
| Mar 31, 2024 | -31.52 Mn |
| Dec 31, 2023 | -34.03 Mn |
| Sep 30, 2023 | -29.52 Mn |
| Jun 30, 2023 | -34.84 Mn |
| Mar 31, 2023 | -37.61 Mn |
| Dec 31, 2022 | -29.02 Mn |
| Sep 30, 2022 | -26.33 Mn |
| Jun 30, 2022 | -32.15 Mn |
| Mar 31, 2022 | -33.59 Mn |
| Dec 31, 2021 | -30.15 Mn |
| Sep 30, 2021 | -33.39 Mn |
| Jun 30, 2021 | -33.41 Mn |